---
title: "Globus Medical Reports Q1 2025: Net Sales Down 1.4%, GAAP Net Income Rises to $75.5M, EPS at $0.54"
description: "Globus Medical reported Q1 2025 financial results with net sales of $598.1 million, down 1.4% year-over-year. GAAP net income rose to $75.5 million, with EPS at $0.54, recovering from a loss of $0.05 "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/239422411.md"
published_at: "2025-05-08T20:26:18.000Z"
---

# Globus Medical Reports Q1 2025: Net Sales Down 1.4%, GAAP Net Income Rises to $75.5M, EPS at $0.54

> Globus Medical reported Q1 2025 financial results with net sales of $598.1 million, down 1.4% year-over-year. GAAP net income rose to $75.5 million, with EPS at $0.54, recovering from a loss of $0.05 in Q1 2024. U.S. sales increased slightly by 0.2%, while international sales fell by 7.7%. The company reaffirmed its 2025 revenue guidance of $2.80 to $2.90 billion and updated non-GAAP EPS guidance to $3.00 to $3.30. The results were impacted by fewer enabling technology sales and supply chain disruptions, but offset by strong U.S. spine performance.

Globus Medical, Inc. announced its financial results for the first quarter of 2025, reporting worldwide net sales of $598.1 million, a decrease of 1.4% compared to the same period in 2024. On a constant currency basis, the decrease was 0.8%. U.S. net sales saw a slight increase of 0.2%, while international net sales fell by 7.7% on an as-reported basis and by 4.6% on a constant currency basis. The decline in net sales was attributed primarily to fewer enabling technology unit sales. The company reported a GAAP net income of $75.5 million for the quarter, marking an increase from the previous year. This improvement was primarily driven by a reduction in amortization costs related to purchase accounting and restructuring costs. The GAAP diluted earnings per share (EPS) was $0.54, a significant recovery from a loss of $0.05 per share in the first quarter of 2024. Non-GAAP diluted EPS increased to $0.68, up from $0.63 in the same quarter of the previous year. Globus Medical also reported net cash provided by operating activities of $177.3 million and a non-GAAP free cash flow of $141.2 million for the quarter. The company reaffirmed its full-year 2025 revenue guidance to be in the range of $2.80 to $2.90 billion and updated its non-GAAP fully diluted earnings per share guidance to be between $3.00 and $3.30. The first quarter results were influenced by softer Enabling Technology deal closures, temporary integration-related supply chain disruptions, and timing issues with international distributor orders, but these were partially offset by strong performance in the core U.S. spine business.

### Related Stocks

- [GMED.US - Globus Medical Inc ](https://longbridge.com/en/quote/GMED.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Globus 医疗的一位高管出售了 10,000 股股票 | 凯莉·哈勒（Kelly Huller），Globus Medical 的执行副总裁、总法律顾问及公司秘书，于 2026 年 2 月 12 日以每股 87.67 美元的价格出售了 10,000 股 A 类普通股，总计 876,700 美元。在 | [Link](https://longbridge.com/en/news/276178102.md) |
| 伊利诺伊州市政退休基金持有价值 275 万美元的 Globus 医疗公司（Globus Medical, Inc.）股票 | 伊利诺伊州市政退休基金在第三季度将其在 Globus Medical, Inc.（纽约证券交易所代码：GMED）的持股增加了 36.4%，目前持有 48,060 股，价值 275 万美元。其他对冲基金也调整了其持仓。首席财务官 Kyle K | [Link](https://longbridge.com/en/news/276050949.md) |
| 在分析师最近上调评级以及初步的第四季度收入更新之后，审视 Globus Medical (GMED) 的估值 | 最近对 Globus Medical (GMED) 的分析师升级突出了积极的初步第四季度收入和利润率扩张。尽管在过去 30 天内股价下跌了 4.78%，但该股票在三年内显示出强劲的 50.52% 的总回报。目前交易价格为 89.00 美元， | [Link](https://longbridge.com/en/news/276259625.md) |
| Globus 医疗｜8-K：2025 财年营收 29.36 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/271840290.md) |
| TD Cowen 基于美国脊柱业务的持续增长和利润率扩张带来的潜在上行空间，给予 Globus 医疗买入评级 | TD Cowen 对 Globus Medical (GMED) 发起了买入评级，指出美国脊柱市场强劲的收入增长潜力。该公司预计，由于创新和市场份额的提升，尽管某些细分市场表现不佳，仍将实现高单位数的增长。他们的财务模型预测到 2028 年 | [Link](https://longbridge.com/en/news/273754485.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.